ClinicalTrials.gg
CompletedNCT01988103Updated May 7, 2020Results posted

Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis

A Phase 2 interventional study of Apremilast and Apremilast in Psoriasis, Psoriatic Arthritis and Psoriasis Arthropatica, sponsored by Amgen. Completed at 56 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-05-07.

Primary conditionArthritis, PsoriaticRegistry: PsoriasisReclassifiedWhy we changed it
Registry
Psoriasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Arthritis, Psoriatic
Why
  1. The study's listed conditions name Arthritis, Psoriatic, a narrower term within Psoriasis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing apremilast in Arthritis, Psoriatic — 3 open to participants now, 3 under way, 1 of them phase 3. apremilast · Arthritis, Psoriatic.

Enrollment
7th of 17
254 · median 219
Started
2013
with 1 other
Phase 2
2 of 17
none open now
Registered
7th of 17
by date
Lead sponsor
11 of 17
Amgen

Among the 17 studies testing apremilast in Arthritis, Psoriatic, this one is the 7th largest by enrollment, is one of 2 that started in 2013, is one of 2 in phase 2, and was the 7th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

3 of the 17 studies testing apremilast in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing apremilast in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

This study will test the clinical effectiveness and safety of two orally administered doses of apremilast compared to placebo in Japanese patients with moderate-to-severe plaque-type psoriasis.

Read the detailed description

This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of apremilast 20 mg twice a day (BID), apremilast 30 mg BID, and placebo in Japanese participants with moderate to severe plaque psoriasis.

03

Conditions studied

  • Psoriasis
  • Psoriatic Arthritis
  • Psoriasis Arthropatica

Browse trials for

Keywords

  • Psoriasis; Psoriatic Arthritis
04

In context

Arthritis, Psoriatic Reclassified

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

This study's enrollment of 254 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.

Browse Arthritis, Psoriatic studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Arthritis, Psoriatic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Psoriasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female Japanese participants greater than or equal to 20 years of age.
  • Diagnosis of chronic, stable plaque psoriasis for at least 6 months prior to screening as defined by: Psoriasis Area Severity Index (PASI) score ≥ 12 and BSA ≥ 10%.
  • Psoriasis which is considered inappropriate for topical therapy (based on severity of disease and extent of affected area) or has not been adequately controlled or treated by topical therapy in spite of at least 4 weeks of prior therapy with at least one topical medication for psoriasis or per label.
  • In otherwise good health based on medical history, physical examination, 12-lead (ECG), serum chemistry, hematology, immunology, and urinalysis.

Exclusion criteria

Exclusion Criteria:

  • Other than psoriasis, history of any and uncontrolled systemic diseases; any condition, including the presence of laboratory abnormalities, which would place the participant at unacceptable risk or confound the ability to interpret the data in the study.

Prior medical history of suicide attempt or major psychiatric illness requiring hospitalization within the last 3 years

  • Pregnant or breastfeeding.
  • History of or ongoing chronic or recurrent infectious disease.
  • Active tuberculosis (TB) or a history of incompletely treated TB.
  • Clinically significant abnormality on 12-lead or on chest radiograph at screening.
  • History of (HIV) infection or have congenital or acquired immunodeficiencies (eg, Common Variable Immunodeficiency).
  • surface antigen or hepatitis B core antibody positive at screening; positive for antibodies to at screening.
  • or history of malignancy, except for treated (ie, cured) basal cell or squamous cell in situ skin carcinomas or treated (ie, cured) cervical intraepithelial neoplasia or carcinoma in situ (CIN) of the cervix with no evidence of recurrence within previous 5 years.
  • Psoriasis flare within 4 weeks of screening.
  • Topical therapy within 2 weeks prior to randomization or systemic therapy for psoriasis or psoriatic arthritis within 4 weeks prior to randomization.
  • Use of etretinate within 2 years prior to randomization for females of child bearing potential (FCBP) or within 6 months for males, and within 4 weeks prior to randomization for non-FCBP.
  • Use of phototherapy: Ultraviolet light B (UVB), Psoralens and long-wave ultraviolet radiation (PUVA) within 4 weeks prior to randomization or prolonged sun exposure or use of tanning booths or other ultraviolet light sources.
  • Use of adalimumab, etanercept, certolizumab pegol, abatacept, tocilizumab, golimumab or infliximab within 12 weeks prior to randomization; use of ustekinumab, alefacept or briakinumab within 24 weeks prior to randomization.
  • Any drug within 4 weeks prior to randomization.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
254 participants (actual)

Study arms

  • Experimental
    Apremilast 20mg

    Apremilast 20 mg tablets orally twice a day (BID)

    Drug: Apremilast · Drug: Placebo

  • Experimental
    Apremilast 30mg

    Apremilast 30 mg tablets orally BID

    Drug: Apremilast · Drug: Placebo

  • Placebo comparator
    Placebo

    Identically-appearing placebo tablets BID for 16 weeks followed by participants being re-randomized in a blinded fasion to apremilast 20 mg or 30mg tablets BID for 52 weeks

    Drug: Placebo

Interventions

  • 20 mg tablet BID for 68 weeks

    Also known as: CC-10004, Otzela

  • 20 mg tablet BID for 68 weeks

    Also known as: CC-10004, Otzela

  • DrugPlacebo

    Placebo tablet BID for 16 weeks

07

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved a 75% Improvement (Response) From Baseline in the Psoriasis Area and Severity Index (PASI-75) at Week 16

    PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing.

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Percentage of Participants Who Achieved a Static Physician's Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With at Least 2 Point Reduction From Baseline to Week 16

    The sPGA is a measure of psoriasis disease severity at the time of evaluation by the Investigator. It does not compare assessments across visits or rely on investigator recall or prior disease. The sPGA is a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examines all of the lesions on the participant and assigns a score ranging from 0 to 5 for thickness, erythema and degree of scaling. Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equals the overall sPGA score.

    Time frame: Baseline to Week 16

  2. Percent Change From Baseline in the Psoriasis Affected Body Surface Area (BSA) at Week 16

    BSA is a measurement of involved skin. The overall BSA affected by psoriasis is estimated based on the palm area of the subject's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area.

    Time frame: Baseline to Week 16

  3. Percent Change From Baseline in the Psoriasis Area and Severity Index (PASI) Score

    The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI is a validated instrument that has become standard in clinical trials for psoriasis. The PASI scores range from 0 to 72, with higher scores reflecting a greater disease severity.

    Time frame: Baseline to Week 16

  4. Percentage of Participants Who Achieved a 50% Improvement From Baseline (Response) Reduction in the PASI-50 at Week 16

    PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement is missing.

    Time frame: Baseline to Week 16

  5. Change From Baseline in Pruritus Visual Analogue Scale 100-mm (VAS) at Week 16

    The pruritus visual analog scale (VAS) was used to measure the amount of itching and discomfort a participant experiences. Participant's assessment of pruritus (Itch) asked: On average, how much itch have you had because of your condition in the past week? Higher scores correspond to more severe symptom or disease. The participant places a vertical line on a 100-mm VAS on which the left-hand boundary represents no itch at all and the right-hand boundary represents the worst itch imaginable. The distance from the vertical line to the left-hand boundary is recorded. VAS scores range from 0 to 100 mm, where higher scores correspond to worse pruritis (itch).

    Time frame: Baseline to Week 16

  6. Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16

    Dermatology Life Quality Index (DLQI) was developed as a practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains 10 items dealing with the participants skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively). The DLQI total score has a possible range from 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.

    Time frame: Baseline to Week 16

  7. Change From Baseline in Mental Component Summary (MCS) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 at Week 16

    SF-36 is a 36-item general health status instrument often used in clinical trials and health services research. It consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better quality of life (better functioning)

    Time frame: Baseline to Week 16

  8. Number of Participants Who Achieved an American College of Rheumatology Criteria (ACR) 20% Improvement (ACR 20)

    The ACR 20 is defined as a 20% improvement in joint tenderness (78 joint count) and joint swelling scores (76 joint count) compared to baseline plus 20% improvements in 3 of the following 5 assessments (compared to baseline): subject global assessment of disease activity (measured on a 100-mm visual analog scale \[VAS\]); physician global assessment of disease activity (measured on a 100-mm VAS); subject self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\] score); subject assessment of pain (measured on a 100-mm VAS); and CRP level.

    Time frame: Baseline to Week 16

  9. Percent Change From Baseline Psoriatic Arthritis Pain Visual Analogue Scale (VAS)

    Change from baseline in psoriatic arthritis pain 100-mm VAS; The participant places a vertical line on a 100-mm VAS on which the left-hand boundary represents no pain at all and the right-hand boundary represents the worst possible pain. The distance from the vertical line to the left-hand boundary is recorded.

    Time frame: Baseline to Week 16

  10. Percent Change From Baseline in Physical Function Assessment Using the Health Assessment Questionnaire Disability Index (HAQ-DI)

    Change from baseline in physical function assessment using HAQ-DI; The HAQ-DI is a 20-question, self-administered instrument that measures the subject's functional ability on a 4-level difficulty scale (0-3, with 0 representing normal or no difficulty; and 3 representing inability to perform). Eight categories of functioning are included: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities.

    Time frame: Baseline to Week 16

  11. Number of Participants With Adverse Events (AE) in the Placebo Controlled Phase

    An AE was any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose.

    Time frame: Baseline to Week 16

  12. Number of Participants With Adverse Events (AE) in the During the Apremilast-exposure Period

    An AE was any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose.

    Time frame: From the first dose of apremilast (either Week 0 or Week 16 for participants originally randomized to placebo who were re-randomized at Week 16) until 28 days after the last dose of apremilast.

08

Results

Posted Mar 20, 2020

Participant flow

Participants must have had a diagnosis of chronic, stable plaque psoriasis at least 6 months prior to screening and which was considered inappropriate for topical therapy (e.g, based on the severity of the disease and extent of affected area) or could not be adequately controlled/treated with topical therapy to qualify for the study.

Placebo-Controlled Phase Week 0-16
Participant flow — Placebo-Controlled Phase Week 0-16
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo-Apremilast 20 mgPlacebo-Apremilast 30 mg
Started84858500
Completed72697600
Not completed1216900
Withdrew: Adverse event310600
Withdrew: Lack of efficacy12200
Withdrew: Withdrawal by subject84100
Active Treatment Phase (Weeks 16-68)
Participant flow — Active Treatment Phase (Weeks 16-68)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo-Apremilast 20 mgPlacebo-Apremilast 30 mg
Started069763635
Completed056653330
Not completed0131135
Withdrew: Adverse event06332
Withdrew: Lack of efficacy01200
Withdrew: Withdrawal by subject05401
Withdrew: Principal investigator signature missing01202
Observational Follow-up Phase
Participant flow — Observational Follow-up Phase
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo-Apremilast 20 mgPlacebo-Apremilast 30 mg
Started1282833633
Completed1279823633
Not completed03100

Outcome measures

PrimaryPercentage of Participants Who Achieved a 75% Improvement (Response) From Baseline in the Psoriasis Area and Severity Index (PASI-75) at Week 16

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a 75% Improvement (Response) From Baseline in the Psoriasis Area and Severity Index (PASI-75) at Week 16
percentage of participantsPlaceboApremilast 20mgApremilast 30mg
Percentage of Participants Who Achieved a 75% Improvement (Response) From Baseline in the Psoriasis Area and Severity Index (PASI-75) at Week 167.123.528.2
Statistical analysis
  • Placebo vs Apremilast 20mg · Chi-squared · p = 0.0032 · Difference: 16.4 · 95% CI 5.8 to 27.0
  • Placebo vs Apremilast 30mg · Chi-squared · p = 0.0003 · Difference: 21.1 · 95% CI 10.1 to 32.1
SecondaryPercentage of Participants Who Achieved a Static Physician's Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With at Least 2 Point Reduction From Baseline to Week 16

The sPGA is a measure of psoriasis disease severity at the time of evaluation by the Investigator. It does not compare assessments across visits or rely on investigator recall or prior disease. The sPGA is a 6-point scale ranging from 0 (clear, except for residual discoloration) to 5 (severe; majority of plaques have severe thickness, erythema, and scaling). The investigator examines all of the lesions on the participant and assigns a score ranging from 0 to 5 for thickness, erythema and degree of scaling. Scores for thickness, erythema and scaling are then summed and the mean of these 3 scores equals the overall sPGA score.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Static Physician's Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With at Least 2 Point Reduction From Baseline to Week 16
percentage of participantsPlaceboApremilast 20mgApremilast 30mg
Percentage of Participants Who Achieved a Static Physician's Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With at Least 2 Point Reduction From Baseline to Week 168.823.929.6
Statistical analysis
  • Placebo vs Apremilast 20mg · Chi-squared · p = 0.0165 · Difference: 15.1 · 95% CI 3.1 to 27.1
  • Placebo vs Apremilast 30mg · Chi-squared · p = 0.0020 · Difference: 20.8 · 95% CI 8.2 to 33.3Missing values were imputed using the LOCF method.
SecondaryPercent Change From Baseline in the Psoriasis Affected Body Surface Area (BSA) at Week 16

BSA is a measurement of involved skin. The overall BSA affected by psoriasis is estimated based on the palm area of the subject's hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total body surface area.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in the Psoriasis Affected Body Surface Area (BSA) at Week 16
percent changePlaceboApremilast 20mgApremilast 30mg
Percent Change From Baseline in the Psoriasis Affected Body Surface Area (BSA) at Week 167.5 ± 5.56-21.6 ± 5.52-30.5 ± 5.51
Statistical analysis
  • Placebo vs Apremilast 20mg · ANCOVA · p = 0.0003 · Mean difference (final values): -29.1 · 95% CI -44.5 to -13.62-sided 95% CI and p-values were based on an analysis of covariance model with treatment arm as a factor and baseline value as a covariate. Means (LS Means) and p-values were adjusted by covariate.
  • Placebo vs Apremilast 30mg · ANCOVA · p = <0.0001 · Mean difference (final values): -38.0 · 95% CI -53.4 to -22.62-sided 95% CI and p-values were based on an analysis of covariance model with treatment arm as a factor and baseline value as a covariate. Means (LS Means) and p-values were adjusted by covariate.
SecondaryPercent Change From Baseline in the Psoriasis Area and Severity Index (PASI) Score

The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI is a validated instrument that has become standard in clinical trials for psoriasis. The PASI scores range from 0 to 72, with higher scores reflecting a greater disease severity.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in the Psoriasis Area and Severity Index (PASI) Score
percent changePlaceboApremilast 20mgApremilast 30mg
Percent Change From Baseline in the Psoriasis Area and Severity Index (PASI) Score-3.7 ± 5.55-33.1 ± 5.51-43.1 ± 5.50
Statistical analysis
  • Placebo vs Apremilast 20mg · ANCOVA · p = 0.0002 · Mean difference (final values): -29.5 · 95% CI -44.9 to -14.02-sided 95% CI and p-values were based on an analysis of covariance model with treatment arm as a factor and baseline value as a covariate. Means (LS Means) and p-values were adjusted by covariate.
  • Placebo vs Apremilast 30mg · ANCOVA · p = <0.0001 · Mean difference (final values): -39.5 · 95% CI -54.9 to -24.12-sided 95% CI and p-values were based on an analysis of covariance model with treatment arm as a factor and baseline value as a covariate. Means (LS Means) and p-values were adjusted by covariate.
SecondaryPercentage of Participants Who Achieved a 50% Improvement From Baseline (Response) Reduction in the PASI-50 at Week 16

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement is missing.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a 50% Improvement From Baseline (Response) Reduction in the PASI-50 at Week 16
percentage of participantsPlaceboApremilast 20mgApremilast 30mg
Percentage of Participants Who Achieved a 50% Improvement From Baseline (Response) Reduction in the PASI-50 at Week 1621.441.250.6
Statistical analysis
  • Placebo vs Apremilast 20mg · Chi-squared · p = 0.0057 · Difference: 19.7 · 95% CI 6.1 to 33.4
  • Placebo vs Apremilast 30mg · Chi-squared · p = <0.0001 · Difference: 29.2 · 95% CI 15.4 to 42.9
SecondaryChange From Baseline in Pruritus Visual Analogue Scale 100-mm (VAS) at Week 16

The pruritus visual analog scale (VAS) was used to measure the amount of itching and discomfort a participant experiences. Participant's assessment of pruritus (Itch) asked: On average, how much itch have you had because of your condition in the past week? Higher scores correspond to more severe symptom or disease. The participant places a vertical line on a 100-mm VAS on which the left-hand boundary represents no itch at all and the right-hand boundary represents the worst itch imaginable. The distance from the vertical line to the left-hand boundary is recorded. VAS scores range from 0 to 100 mm, where higher scores correspond to worse pruritis (itch).

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Pruritus Visual Analogue Scale 100-mm (VAS) at Week 16
units on a scalePlaceboApremilast 20mgApremilast 30mg
Change From Baseline in Pruritus Visual Analogue Scale 100-mm (VAS) at Week 167.1 ± 2.86-7.5 ± 2.84-17.7 ± 2.83
Statistical analysis
  • Placebo vs Apremilast 20mg · ANCOVA · p = 0.0003 · Mean difference (final values): -14.6 · 95% CI -22.6 to -6.72-sided 95% CI and p-values were based on an analysis of covariance model with treatment arm as a factor and baseline value as a covariate. Means (LS Means) and p-values were adjusted by covariate.
  • Placebo vs Apremilast 30mg · ANCOVA · p = <0.0001 · Mean difference (final values): -24.8 · 95% CI -32.7 to -16.92-sided 95% CI and p-values were based on an analysis of covariance model with treatment arm as a factor and baseline value as a covariate. Means (LS Means) and p-values were adjusted by covariate. Missing values were imputed using the LOCF method.
SecondaryChange From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16

Dermatology Life Quality Index (DLQI) was developed as a practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains 10 items dealing with the participants skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively). The DLQI total score has a possible range from 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16
units on a scalePlaceboApremilast 20mgApremilast 30mg
Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 161.3 ± 0.53-0.5 ± 0.53-2.2 ± 0.52
Statistical analysis
  • Placebo vs Apremilast 20mg · ANCOVA · p = 0.0204 · Mean difference (final values): -1.7 · 95% CI -3.2 to -0.32-sided 95% CI and p-values were based on an analysis of covariance model with treatment arm as a factor and baseline value as a covariate. Means (LS Means) and p-values were adjusted by covariate.
  • Placebo vs Apremilast 30mg · ANCOVA · p = <0.0001 · Mean difference (final values): -3.5 · 95% CI -4.9 to -2.02-sided 95% CI and p-values were based on an analysis of covariance model with treatment arm as a factor and baseline value as a covariate. Means (LS Means) and p-values were adjusted by covariate.
SecondaryChange From Baseline in Mental Component Summary (MCS) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 at Week 16

SF-36 is a 36-item general health status instrument often used in clinical trials and health services research. It consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better quality of life (better functioning)

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Mental Component Summary (MCS) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 at Week 16
units on a scalePlaceboApremilast 20mgApremilast 30mg
Change From Baseline in Mental Component Summary (MCS) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 at Week 16-1.59 ± 0.953-0.71 ± 0.9530.27 ± 0.948
Statistical analysis
  • Placebo vs Apremilast 20mg · ANCOVA · p = 0.5149 · Mean difference (final values): 0.88 · 95% CI -1.78 to 3.532-sided 95% CI and p-values were based on an analysis of covariance model with treatment arm as a factor and baseline value as a covariate. Means (LS Means) and p-values were adjusted by covariate.
  • Placebo vs Apremilast 30mg · ANCOVA · p = 0.1693 · Mean difference (final values): 1.85 · 95% CI -0.79 to 4.502-sided 95% CI and p-values were based on an analysis of covariance model with treatment arm as a factor and baseline value as a covariate. Means (LS Means) and p-values were adjusted by covariate.
SecondaryNumber of Participants Who Achieved an American College of Rheumatology Criteria (ACR) 20% Improvement (ACR 20)

The ACR 20 is defined as a 20% improvement in joint tenderness (78 joint count) and joint swelling scores (76 joint count) compared to baseline plus 20% improvements in 3 of the following 5 assessments (compared to baseline): subject global assessment of disease activity (measured on a 100-mm visual analog scale \[VAS\]); physician global assessment of disease activity (measured on a 100-mm VAS); subject self-assessment of physical function (Health Assessment Questionnaire - Disability Index \[HAQ-DI\] score); subject assessment of pain (measured on a 100-mm VAS); and CRP level.

Time frame:
Baseline to Week 16

No measurements were reported for this outcome.

SecondaryPercent Change From Baseline Psoriatic Arthritis Pain Visual Analogue Scale (VAS)

Change from baseline in psoriatic arthritis pain 100-mm VAS; The participant places a vertical line on a 100-mm VAS on which the left-hand boundary represents no pain at all and the right-hand boundary represents the worst possible pain. The distance from the vertical line to the left-hand boundary is recorded.

Time frame:
Baseline to Week 16

No measurements were reported for this outcome.

SecondaryPercent Change From Baseline in Physical Function Assessment Using the Health Assessment Questionnaire Disability Index (HAQ-DI)

Change from baseline in physical function assessment using HAQ-DI; The HAQ-DI is a 20-question, self-administered instrument that measures the subject's functional ability on a 4-level difficulty scale (0-3, with 0 representing normal or no difficulty; and 3 representing inability to perform). Eight categories of functioning are included: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities.

Time frame:
Baseline to Week 16

No measurements were reported for this outcome.

SecondaryNumber of Participants With Adverse Events (AE) in the Placebo Controlled Phase

An AE was any noxious, unintended, or untoward medical occurrence, that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose.

Time frame:
Baseline to Week 16
Reported as:
Number · participants
Number of Participants With Adverse Events (AE) in the Placebo Controlled Phase
participantsPlaceboApremilast 20mgApremilast 30mg
≥ At least 1 TEAE354944
≥ 1 Drug-related TEAE81825
≥ At least 1 Severe TEAE140
≥ 1 Serious TEAE040
Any Serious Drug-related TEAE020
≥ 1 TEAE leading to Drug Interruption220
≥ 1 TEAE Leading to Drug Withdrawal4106
≥ 1 TEAE Leading to Death000
SecondaryNumber of Participants With Adverse Events (AE) in the During the Apremilast-exposure Period

An AE was any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) was considered an AE. A serious AE (SAE) is any untoward adverse event that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly or birth defect, or a condition that may jeopardize the patient or may require intervention to prevent one of the outcomes listed above. An AE is a treatment emergent AE if the AE start date is on or after the date of the first dose of study drug and no later than 28 days after the last dose.

Time frame:
From the first dose of apremilast (either Week 0 or Week 16 for participants originally randomized to placebo who were re-randomized at Week 16) until 28 days after the last dose of apremilast.
Reported as:
Number · participants
Number of Participants With Adverse Events (AE) in the During the Apremilast-exposure Period
participantsApremilast 20mgApremilast 30mg
≥ At Least 1 TEAE9489
≥ 1 Drug-related TEAR3437
≥ At Least 1 Severe TEAE122
≥ 1 Serious TEAE112
Any Serious Drug-related TEAE50
≥ 1 TEAE leading to Drug Interruption62
≥ 1 TEAE Leading to Drug Withdrawal1910
≥ 1 TEAE Leading to Death10

Adverse events

Collected over AEs are reported for the 16-week placebo-controlled phase and up to 68 weeks for those who received apremilast during the study; TEAEs were recorded from the date of the first dose of IP received to no later than 28 days after the last dose of IP. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Weeks 0-16)—0/84 (0%)9/84 (10.7%)
Apremilast 20mg BID (Weeks 0-16)—4/85 (4.7%)16/85 (18.8%)
Apremilast 30mg BID (Weeks 0-16)—0/85 (0%)18/85 (21.2%)
Apremilast 20mg BID (Weeks 0-68)—11/121 (9.1%)35/121 (28.9%)
Apremilast 30mg BID (Weeks 0-68)—2/120 (1.7%)40/120 (33.3%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPlacebo (Weeks 0-16)Apremilast 20mg BID (Weeks 0-16)Apremilast 30mg BID (Weeks 0-16)Apremilast 20mg BID (Weeks 0-68)Apremilast 30mg BID (Weeks 0-68)
CholelithiasisHepatobiliary disorders0/841/850/852/1210/120
Coronary artery stenosisCardiac disorders0/841/850/851/1210/120
Arthritis bacterialInfections and infestations0/841/850/851/1210/120
Cerebral haemorrhageNervous system disorders0/841/850/851/1210/120
PeriodontitisGastrointestinal disorders0/840/850/850/1211/120
Intraocular pressure increasedInvestigations0/840/850/850/1211/120
Cardiac failure congestiveCardiac disorders0/840/850/851/1210/120
Bile duct stoneHepatobiliary disorders0/840/850/851/1210/120
PneumoniaInfections and infestations0/840/850/851/1210/120
Diabetes mellitusMetabolism and nutrition disorders0/840/850/851/1210/120
Most frequent other events
Most frequent other events
EventPlacebo (Weeks 0-16)Apremilast 20mg BID (Weeks 0-16)Apremilast 30mg BID (Weeks 0-16)Apremilast 20mg BID (Weeks 0-68)Apremilast 30mg BID (Weeks 0-68)
NasopharyngitisInfections and infestations7/8410/8510/8528/12135/120
DiarrhoeaGastrointestinal disorders1/847/858/8510/12112/120
Abdominal discomfortGastrointestinal disorders1/841/856/853/1218/120

Baseline characteristics

Modified Intent-to-treat Population = (mITT) population consisted of all participants who were randomized and received at least one dose of investigational product (IP). Participants were included in the treatment group in which they were randomized.

Age, Continuous
Age, Continuous(years)PlaceboApremilast 20 mgApremilast 30 mgTotal
Mean48.3 ± 11.9852.2 ± 12.5451.7 ± 12.7350.8 ± 12.49
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboApremilast 20 mgApremilast 30 mgTotal
Female22161452
Male626971202
Region of Enrollment
Region of Enrollment(Participants)PlaceboApremilast 20 mgApremilast 30 mgTotal
Japan848585254
09

Study locations

56 sites
  • Ekihigashi Hifuka Clinic
    Fukuoka-shi, Fukuoka 812-0013, Japan
  • Tsutsui Clinic Dermatology & Plastic Surgery
    Fukuoka-shi, Fukuoka 813-0042, Japan
  • Yano Hifuka Hinyokika Clini
    Fukuoka-shi, Fukuoka 814-0013, Japan
  • Fukuoka University Hospital
    Fukuoka-shi, Fukuoka 814-0180, Japan
  • HATAMOTO Derma Clinic
    Fukuoka-shi, Fukuoka 815-0075, Japan
  • Tomoko Matsuda Dermatological Clinic
    Fukuoka-shi, Fukuoka 819-0167, Japan
  • TASHIRO Dermatological Clinic
    Iizuka-shi, Fukuoka 820-0040, Japan
  • Okubo Skin Care and Clinic
    Itoshima-shi, Fukuoka 819-1108, Japan
  • Matsuda Dermatology Clinic For Skin, Hair, Nail Diseases
    Itoshima-shi, Fukuoka 819-1116, Japan
  • Kyusyu Rosai Hospital
    Kitakyushu-shi, Fukuoka 800-0296, Japan
  • Kitakyushu Municipal Medical Center
    Kitakyushu, Fukuoka 802-0077, Japan
  • Kyushu Kosei Nenkin Hospital
    Kitakyushu, Fukuoka 806-8501, Japan
  • Kurume University Hospital
    Kurume, Fukuoka 830-0011, Japan
  • Matsuo Clinic
    Nishi-Ku, Fukuoka 819-0373, Japan
  • Yame General Hospital
    Yame, Fukuoka 834-0034, Japan
  • Kokubu Medical Office Abashiri Dermatology Clinic
    Abashiri-shi, Hokkaido 093-0016, Japan
  • Chitose Dermatology Plastic Surgery Clinic
    Chitose-shi, Hokkaido 066-0021, Japan
  • Asanuma Dermatology Clinic
    Chitose-shi, Hokkaido 066-0064, Japan
  • Kokubu Dermatology
    Kitami-shi, Hokkaido 090-0832, Japan
  • Sapporo Skin Clinic
    Sapporo-shi, Hokkaido 060-0063, Japan
  • Fukuzumi Dermatology Clinic
    Sapporo-shi, Hokkaido 062-0042, Japan
  • Kobe City Medical Center
    Kobe City, Hyogo 653-0013, Japan
  • Hitachi General Hospital
    Hitachi, Ibaraki 317-0077, Japan
  • Tokyo Medical University Ibaraki Medical Center
    Inashiki-gun, Ibaraki 300-0395, Japan
  • Kanto Rosai Hospital
    Kawasaki City, Kanagawa 211-8510, Japan
  • Kawasaki Saiwai Clinic
    Kawasaki-shi, Kanagawa 212-0016, Japan
  • Teikyo University School of Medicine University Hospital
    Kawasaki, Kanagawa 213-8507, Japan
  • Sagamihara National Hospital
    Sagamihara, Kanagawa 252-0392, Japan
  • Queen's Square Medical Facilities
    Yokohama-shi, Kanagawa 220-6208, Japan
  • Yokohama City University Hospital
    Yokohama, Kanagawa 213-8507, Japan
  • Nomura Dermatology Clinic
    Yokohoma City, Kanagawa 221-0825, Japan
  • Yokosuka Kyosai Hospital
    Yokosuka, Kanagawa 238-8558, Japan
  • Kumamoto Shinto General Hospital
    Kumamoto City, Kumamoto 862-0975, Japan
  • Kosumi lin
    Kumamoto-shi, Kumamoto 860-0016, Japan
  • Kume Derma Clinic
    Sakai-Shi, Osaka 593-8324, Japan
  • SANRUI Dermatology
    Saitama-shi, Saitama 330-0854, Japan
  • Jichi Medical University Hospital
    Shimotsuke-shi, Tochigi 329-0498, Japan
  • Sugai Dermatologist Park Side Clinic
    Utsunomiya-shi, Tochigi 321-0954, Japan
  • Kayaba Dermatology Clinic
    Cyu-o-ku, Tokyo 103-0016, Japan
  • Tokai University School of Medicine
    Hachioji, Tokyo 192-0032, Japan
  • Inagi Municipal Hospital
    Inagi, Tokyo 206-2801, Japan
  • TSUTSUMI Clinic
    Itabasi-Ku, Tokyo 174-0071, Japan
  • Koto Hospital
    Koto-ku, Tokyo 136-0072, Japan
  • Maruyama Dermatology Clinic
    Koto-ku, Tokyo 136-0074, Japan
  • OIZUMI HANAWA Clinic
    Nerima-ku, Tokyo 178-0063, Japan
  • Kitahara Dermatology Clinic
    Setagaya-ku, Tokyo 158-0094, Japan
  • NAOKO Dermatology Clinic
    Setagaya-ku, Tokyo 158-0097, Japan
  • Mita Dermatology Clinic
    Shiba Minato-k, Tokyo 108-0014, Japan
  • NTT Medical Center Tokyo
    Shinagawa-ku, Tokyo 141-8625, Japan
  • Tokyo Medical University Hospital
    Shinjyuku-ku, Tokyo 160-0023, Japan
  • Taneda Dermatology Clinic
    Suginami-ku, Tokyo 166-0015, Japan
  • Federation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital
    Tachikawa, Tokyo 190-8531, Japan
  • Shakaihoken Simonoseki Kosei Hospital
    Shimonoseki-shi, Yamaguchi 750-0061, Japan
  • Matsuo Clinic
    Fukuoka, 719-0373, Japan
  • AMC Nishiumeda Clinic
    Osaka, 530-0001, Japan
  • Tokyo Center Clinic
    Tokyo, 103-0028, Japan
10

References and documents

Publications

  • Ohtsuki M, Okubo Y, Komine M, Imafuku S, Day RM, Chen P, Petric R, Maroli A, Nemoto O. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial. J Dermatol. 2017 Aug;44(8):873-884. doi: 10.1111/1346-8138.13829. Epub 2017 Apr 9. PubMed 28391657 ↗
  • Ohtsuki M, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol. 2018 Sep;45(9):1053-1062. doi: 10.1111/1346-8138.14504. Epub 2018 Jun 15. PubMed 29905383 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2013 to primary completion in Nov 2014, 16 months.

Results were first posted in Mar 2020, 5 years 4 months after primary completion. A results delay was requested in Sep 2015.

Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2013
First posted
Nov 20, 2013
StartActual
Jul 9, 2013
Primary completionActual
Nov 20, 2014
CompletionActual
Dec 15, 2015
Results delay requested
Sep 29, 2015
Results first posted
Mar 20, 2020
Last update
May 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01988103
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Nov 20, 2013
Start date
Jul 9, 2013
Primary completion
Nov 20, 2014
Completion
Dec 15, 2015
Results posted
Mar 20, 2020
Last update
May 7, 2020

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion